TEST:

VENTANA PD-L1 (SP142) Assay

The #OncoAlertTopTweet 🚨 Day 2⃣ #ESMO22 Tweet @DrChoueiri 🇺🇸 PD-L1 antibodies for testing matter! @drenriquegrande 🇪🇸looking at a study in adjuvant bladder cancer: SP142 vs 22C3 Best, @weoncologists ()

We went through this in TNBC- for Atezo SP142 is the best test.. 22 C3 captures more patients . Only 1% was SP142+ and 22C3 - (@RenoHemonc)

IMvigor130 exploratory analysis shows PD-L1 expression by SP142 co-localised with dentritic cells and longer OS with atezolizumab in SP142 IC2/3 vs IC0/1 tumors in pts with metastatic urothelial cancer. Fantastic presentation by @drenriquegrande. #ESMO22 @myESMO (@wearemedsir)

PD-L1 antibodies for testing matter! Here with @drenriquegrande looking at a study in adjuvant bladder cancer: SP142 vs 22C3 @myESMO #ESMO22 @OncoAlert (@DrChoueiri)

#ESMO22 @myESMO Abs#1735O:Post exploratory analysis from ph3 IMvigor130 #bladdercancer 👉 PD-L1 expressing dendritic cells may underlie the longer OS with atezo in SP142 IC2/3 vs IC0/1 tumors in pts with mUC 👉 https://t.co/IyrSTix8C8 @drenriquegrande @neerajaiims @oncoalert ()

@hoperugo moves onto #KN355 discussion ✅ PDL1 CPS of 10 is proper cutoff ‼️ reminder: CPS and SP142 do NOT completely overlap ❓ remain how long to continue immuno 💯 there are immune differences between early and advanced disease #bcsm #SABCS21 @OncoAlert (@ErikaHamilton9)

Another “gee whiz” moment for immunotherapy: FDA approves an uncommonly used PD-L1 assay (SP263) as CDx for Adjuvant Atezolizumab in Stage II-IIIA NSCLC (IMpower010 trial) where SP142 used for eligibility. Yet most PD-L1 in USA is Dako22c3 & will remain so https://t.co/4rKEFKn0VF (@drgandara)

This is from @hoperugo recent talk comparing 22C3 CPS 10 to SP142. I suppose the 10% of TnBC patients that are SP142+ and CPS10 negative are now out of an immunotherapy option. #bcsm https://t.co/xfyV61kzhi (@drsarahsam)

With recent shocks in the TNBC IO field, it’s a good time to re-check this great analysis by @hoperugo & al 👉22C3+ much more common than SP142+ 👉by using 22C3 CPS>10 threshold, low concordance was noted with SP142 (22% SP142+ patients are missed) #bcsm https://t.co/aAKFsgUi1T (@PTarantinoMD)

Nice work indeed @stolaney1 Carful interpretation on apparently disappointing results: only 7% PD-L1+ (SP142) unusually low, in not heavily pretreated patients, 61% 1st/2nd line (bad luck?) Very good translation study. #bcsm (@BianchiniGP)

Do you know the important elements to quickly assess the tonsil tissue control before reading a TNBC case stained with PD-L1 (SP142) assay? (@RocheDiaUSA)

Remember that PD-L1 testing was performed using SP142 and then later SP263 assay #LCSM #ASCO21 @ASCO (@CharuAggarwalMD)

Delighted to share our work on dual PD-L1 expression (SP142 & SP263) performance for whole slides from matched bladder cancer tissue (TURBT, RC & LN+) @joostboormans @SpringerPath #PathTwitter cc @Markuseckstein3 @AndreaNecchi @ewanagibb @IBCN1997 https://t.co/8vHi8onHZ5 (@JoepJdeJong)

Should be a nice AI project than pathologists wasting time bean counting. All 3 scores can be reported and oncologist can chose the appropriate one depending on indication. TPS for lung , IC/ SP142 for TNBC , CPS/22C3 for GI, Bladder.. (@RenoHemonc)

@JenniferLitton reviews #immuno in #TNBC 📍IMpassion130 shows benefit for PD-L1 IC+ TNBC, OS improved by 7 months 📍anatomical variance in + testing (liver least likely +) 📍SP142 does not correlate with 22C3 for atezo benefit #SABCS20 @OncoAlert #bcsm (@ErikaHamilton9)

Request help w 45 y/o met TNBC pt on pacli. PD-L1 < 1% IC SP142. NGS w WRN loss, CCND1 ampl, FGFR2 ampl. Plat-Olap? FGFR inh? cdk4/6 inh in TNBC? ⁦@Dr_R_Kurzrock⁩ ⁦@KalinskyKevin⁩ ⁦@MCristofanill⁩ ⁦@cancermd⁩ ⁦@DrDawnHershman⁩ ⁦@oncologician⁩ (@SewantiLimaye)

#ESMO20 👇#TMB and outcomes in 1⃣line M+ #TNBC < #IMpassion130 🔹median TMB 4,39 mut/Mb 🔹no correlation between TMB and PD-L1 SP142 nor #sTILs 🔹trend between ↗️TMB and ↗️clinical benefit of #atezolizumab in PD-L1+ but not in PD-L1- #OncoAlert #bcsm @hoperugo @LoiSher (@kevinpunie)